Mikkeli Central Hospital   Report issue

Academic/Hospital Phase 2 Phase 4
Founded: Mikkeli Finland

Organization Overview

First Clinical Trial
2009
NCT01022567
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Mikkeli Central Hospital

Active Ingredients

Drugs in Phase 4 Trials (3)

imatinib (gleevec) (1 trial)

infliximab (remicade) (1 trial)

remdesivir (1 trial)

Drugs in Phase 2 Trials (2)

cyclophosphamide (cytoxan) (1 trial)

sargramostim (leukine) (1 trial)

Drugs in Other Trials (2)

ertapenem (invanz) (2 trials)

moxifloxacin (avelox) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Multiple Myeloma (Phase 2)

Neoplasms, Plasma Cell (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial APIs: 7